[ADA2015]中国荟萃分析：2型188bet在线平台网址降糖药物的安慰剂效应®金宝搏网站登录技巧 -网聚医学的力量

[ADA2015]中国荟萃分析：2型188bet在线平台网址降糖药物的安慰剂效应

作者：医脉通来源：医脉通日期：2015-06-12

导读

总体上，综合所有研究，安慰剂治疗能使HbA1c相比基线降低0.03%，但无显著统计学意义（(95% CI, -0.17% to 0.11%, p>0.05）。结论：该荟萃分析为2型188bet在线平台网址降糖治疗中的安慰剂效应提供了全面临床证据。

关键字： Placebo | 降糖药物 | 安慰剂效应 | 噻唑烷二酮类 | 磺脲类药物

　　2015年第75届美国188bet在线平台网址协会（ADA）科学年会在美国波士顿召开。北京大学人民医院内分泌代谢科纪立农教授团队的的一项荟萃分析结果在ADA2015年会普通壁报专场（General Poster Session）上发布。该研究通过对248项研究的荟萃分析，评估2型188bet在线平台网址降糖治疗中的安慰剂效应。以下是研究摘要译文。

　　目的：安慰剂是指对于疾病没有确切的药物治疗作用、但可能产生非特异性心理或生理积极作用的治疗手段。本研究旨在评估2型188bet在线平台网址降糖治疗中安慰剂的影响。

　　方法：入选MEDLINE、EMBASE及CENTRAL数据库2013年12月之前的研究。所有研究都是双盲、有安慰对照、在2型188bet在线平台网址患者中开展的研究，研究持续时间≥12周、且采用与基线相比HbA1c的变化来评估降糖疗效。最终有248项研究入选。

　　结果：在对比磺脲类药物与安慰剂的研究中，安慰剂治疗使HbA1c降低0.03%（95% CI, 0.37% to 0.44%, p>0.05）；在对比二甲双胍与安慰剂的研究中，安慰剂治疗使HbA1c降低0.19%（95% CI, 0.18% to 0.57%, p>0.05）；在对比糖苷酶抑制剂与安慰剂的研究中，安慰剂治疗使HbA1c降低0.06%（95% CI, 0.12% to 0.23%, p>0.05）；在对比噻唑烷二酮类药物与安慰剂的研究中，安慰剂治疗使HbA1c降低0.09%（95% CI, -0.06% to 0.23%, p>0.05）；在对比DPP-4抑制剂与安慰剂的研究中，安慰剂治疗使HbA1c降低0.09%（95% CI, -0.20% to 0.03%, p>0.05）；在对比SGLT-2抑制剂与安慰剂的研究中，安慰剂治疗使HbA1c降低0.26%（95% CI, -0.54% to 0.02%, p>0.05）；在对比GLP-1类似物与安慰剂的研究中，安慰剂治疗使HbA1c降低0.11%（95% CI, -0.30% to 0.08%, p>0.05）。总体上，综合所有研究，安慰剂治疗能使HbA1c相比基线降低0.03%，但无显著统计学意义（(95% CI, -0.17% to 0.11%, p>0.05）。荟萃回归分析显示，患者年龄及女性所占比例与安慰剂组HbA1c相对于基线时的变化幅度呈负相关。

　　结论：该荟萃分析为2型188bet在线平台网址降糖治疗中的安慰剂效应提供了全面临床证据。安慰剂治疗可使HbA1c降低0.03%，但无显著统计学意义。

　　【研究摘要】　　

Abstract Number:	1137-P
Title:	Placebo Effect of Hypoglycemic Drugs in Type 2 Diabetes—A Meta-analysis
Authors:	XIAOLING CAI, WENJIA YANG, LINGLI ZHOU, XUEYAO HAN, LINONG JI, Beijing, China
Abstract:	Placebo has been defined as any therapy that is used for its nonspecific psychological and physiologic effect but has no specific pharmacologic impact on the condition being treated. The aim of this study is to evaluate placebo effect of hypoglycemic treatment in type 2 diabetes. The MEDLINE , EMBASE , CENTRAL were searched until Dec 2013 and qualified studies were included. All the studies were double blind, placebo-controlled randomized trials in type 2 diabetes patients; study length of ≥12 weeks with the efficacy evaluated by changes in HbA1c from baseline in groups. 248 studies were included. In studies compared SU with placebo, treatment with placebo led to a HbA1c change of 0.03% (95% CI, 0.37% to 0.44%, p>0.05); in studies compared MET with placebo, treatment with placebo led to a HbA1c change of 0.19% (95% CI, 0.18% to 0.57%, p>0.05); in studies compared AGI with placebo, treatment with placebo led to a HbA1c change of 0.06% (95% CI, 0.12% to 0.23%, p>0.05); in studies compared TZD with placebo, treatment with placebo led to a HbA1c change of 0.09% (95% CI, -0.06% to 0.23%, p>0.05); in studies compared DPP-IV inhibitors with placebo, treatment with placebo led to a HbA1c change of -0.09% (95% CI, -0.20% to 0.03%, p>0.05); in studies compared SGLT2 with placebo, treatment with placebo led to a HbA1c change of -0.26% (95% CI, -0.54% to 0.02%, p>0.05); in studies compared GLP-1 analogue with placebo, treatment with placebo led to a HbA1c change of -0.11% (95% CI, -0.30% to 0.08%, p>0.05). Totally, in all studies, treatments with placebo led an HbA1c change from baseline of -0.03% without significance (95% CI, -0.17% to 0.11%, p>0.05). Meta-regression analyses revealed that the age of patients and percentage of female were negatively associated with HbA1c changes from baseline in placebo group. This meta-analysis provided comprehensive clinical evidence on placebo effect of hypoglycemic treatment in type 2 diabetes. Treatment with placebo led an HbA1c change from baseline of -0.03% without significance.